Compounds · Cagrilintide & amylin analogues · continued

Nausea profile of amylin analogues compared with GLP-1 agonists posts 31–60

Compounds › Cagrilintide & amylin analogues cagrilintide amylin analogues cagrisema

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.

sourced_claimsTL3Regular27 Feb 2026#31

m.almeida, post #10: Picking up post #9: that is the part I would want checked first. The version of nausea profile of amylin analogues that circulates here is a simplification of a simplification. It is not wrong, but it has lost the conditions under which it holds, and those conditions are where the interesting cases live. Go to post

On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual.

I would call that likely rather than established.

23 likes in reply to #10 5mo

ro.zielinskiTL228 Feb 2026#32

ni.kravchenko, post #18: Historical amylin analogues: pramlintide was the only long-acting amylin analogue licensed for some time and its poor adherence was a known limitation. A weekly formulation addresses that practical barrier. I have changed my mind on this once already, so take it as current rather than settled. Go to post

Comparing an amylin analogue to an incretin agonist on weight change alone misses that they were developed to be used together rather than instead of each other.

Correct me on the arithmetic if it is wrong; I would rather know.

0 likes in reply to #18 5mo

dr.villanuevaTL3Physician28 Feb 2026#33

What is genuinely unknown about long-term amylin agonism: real-world response rates, whether effect is durable with continued use, whether satiety adaptation occurs over months or years, safety profile in populations not enrolled in the trials.

If the premise is wrong, everything after it is decoration.

1 like 5mo

s.grimaldiTL21 Mar 2026#34

Where I part company with post #30, and it is a narrow parting.

Nausea profile of amylin analogues is a good example of a question where the honest answer is boring and the interesting answers are unsupported. I would go with boring.

6 likes 5mo

microgramsTL2Regular1 Mar 2026 · edited#35

Sensible. I would want the same detail before I acted on it either.

31 likes 5mo

a.adeyemiTL22 Mar 2026#36

p.krastev, post #16: I read post #12 twice before replying, because I had assumed the opposite. What is genuinely unknown about long-term amylin agonism: real-world response rates, whether effect is durable with continued use, whether satiety adaptation occurs over months or years, safety profile in populations not enrolled in the trials. Go to post

The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a mass consistent with the proposed structure is a necessary condition and not a sufficient one.

For what it is worth, the same held on the two occasions I checked.

0 likes in reply to #16 5mo

priorauth_notesTL2Regular2 Mar 2026#37

Amylin analogues affect gastric emptying as well, so the mechanism overlaps the incretins in at least one place. That overlap is part of why the combination's tolerability profile is not simply the sum of the two.

Adding it in case it saves somebody the afternoon it cost me.

3 likes 5mo

m.kjaerTL23 Mar 2026#38

Gastric emptying: both amylin and GLP-1 slow it, through partly overlapping but distinct mechanisms. Whether the slowing at a higher magnitude produces disproportionate nausea or is tolerable is a question phase 3 exists to answer.

I would not lead a decision with this, but I would not ignore it either.

10 likes 5mo

a.reyesTL4 Admin3 Mar 2026#39

Historical amylin analogues: pramlintide was the only long-acting amylin analogue licensed for some time and its poor adherence was a known limitation. A weekly formulation addresses that practical barrier.

0 likes 5mo

k.dahlbergTL24 Mar 2026#40

h.frisk, post #30: Anyone submitting this for independent testing should say in the submission that it is an amylin analogue rather than an incretin. Method selection differs and a default incretin gradient is not necessarily the right one. Go to post

On post #38 — agreed on the reasoning, with one qualification.

I would keep nausea profile of amylin analogues and the decision it usually gets used for separate in this thread. They are related and they are not the same question, and merging them is why the last one went badly.

1 like in reply to #30 5mo

n.duarteTL24 Mar 2026#41

Cagrilintide is a long-acting amylin analogue, which puts it in a different mechanistic family from the incretin agonists it is usually discussed alongside. Amylin signalling contributes to satiety through a distinct pathway.

13 likes 5mo

crossref_checkTL3Wiki editor4 Mar 2026#42

c.rasmussen, post #1: Nausea profile of amylin analogues compared with GLP-1 agonists Writing it up because I had to work it out twice and would rather nobody else did. I have spent a fortnight trying to pin nausea profile of amylin analogues down and I want to set out where I have got to, because I suspect the honest answer is duller than the thread this… Go to post

Narrowing post #39, because the general version has more than one answer.

Nausea profile of amylin analogues looks different depending on whether you are reading the primary literature or the summaries of it, and the difference is not in our favour.

4 likes in reply to #1 5mo

k.asanteTL25 Mar 2026#43

s.grimaldi, post #34: Where I part company with post #30, and it is a narrow parting. Nausea profile of amylin analogues is a good example of a question where the honest answer is boring and the interesting answers are unsupported. I would go with boring. Go to post

The practical version of nausea profile of amylin analogues is three sentences long. The rigorous version is three pages and reaches the same conclusion with the conditions attached.

0 likes in reply to #34 5mo

c.okaforTL3Regular5 Mar 2026#44

That is a cleaner way of putting what I was circling around.

27 likes 5mo

b.friskTL26 Mar 2026#45

I read post #43 twice before replying, because I had assumed the opposite.

Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The hypothesis behind combination is two complementary satiety mechanisms with one injection.

Speaking for myself and not for anyone else who has posted here.

19 likes 5mo

r.jhannsdttirTL3Regular6 Mar 2026 · edited#46

v.kjaer, post #6: Adding the measurement that post #5 says would settle it. Reconstitution at higher concentrations is worth avoiding for aggregation-prone material. The published formulation work generally uses lower concentrations than people reconstitute to at home, and there is a reason for that. I keep a log of this specifically because memory is… Go to post

Post #43 answers the question as asked. The question underneath it is different.

Native amylin has awkward physical properties — it aggregates readily, which is why a stable analogue is a pharmaceutical achievement rather than a formulation detail.

Not the whole picture, but the part of it I can speak to.

8 likes in reply to #6 5mo

v.bergstromTL27 Mar 2026#47

crossref_check, post #42: Narrowing post #39, because the general version has more than one answer. Nausea profile of amylin analogues looks different depending on whether you are reading the primary literature or the summaries of it, and the difference is not in our favour. Go to post

Where I would push back on the nausea profile of amylin analogues consensus is the confidence, not the direction. The direction looks right. The confidence is borrowed.

0 likes in reply to #42 5mo

VPoulsenTL3Regular7 Mar 2026#48

Small methodological point on nausea profile of amylin analogues: repeating a measurement is cheap and resolves most of what is being argued about here at no cost to anyone.

0 likes 5mo

c.vasquezTL27 Mar 2026#49

Post #47 describes the usual case. This is about the unusual one.

The rule of thumb is fine; the edge cases are where it earns its keep.

26 likes 5mo

a.finnegan_rdTL2Dietitian8 Mar 2026#50

a.vermeulen, post #12: Everything in post #9 holds. The case it does not cover is the one I have. Comparing an amylin analogue to an incretin agonist on weight change alone misses that they were developed to be used together rather than instead of each other. Go to post

For anyone arriving from searches on "amylin agonist": this subcategory discusses published clinical evidence and what it does and does not establish. It does not endorse or recommend the compounds discussed.

I would treat the number as indicative rather than as a measurement.

12 likes in reply to #12 5mo

s.coelhoTL28 Mar 2026#51

priorauth_notes, post #37: Amylin analogues affect gastric emptying as well, so the mechanism overlaps the incretins in at least one place. That overlap is part of why the combination's tolerability profile is not simply the sum of the two. Adding it in case it saves somebody the afternoon it cost me. Go to post

Adding the boring version of nausea profile of amylin analogues, because the interesting version keeps getting posted and the boring one is usually right.

Check the ordinary explanations, in order, and stop when one of them accounts for what you are seeing. Most of the time the second one does.

20 likes in reply to #37 5mo

j.mwangiTL4 Moderator9 Mar 2026#52

c.vasquez, post #49: Post #47 describes the usual case. This is about the unusual one. On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual. The rule of thumb is fine; the edge cases are… Go to post

The confident answers on nausea profile of amylin analogues and the well-sourced answers are not the same answers, which is the most useful thing I have learned reading this category.

0 likes in reply to #49 5mo

e.kuuselaTL29 Mar 2026#53

Taking post #50 at face value and following it one step further.

Nausea appears in the amylin-analogue literature as it does in the incretin literature, and the two are not additive in a simple way when the drugs are combined. The combination trials report tolerability separately for that reason.

That distinction has done more work for me than anything else in this category.

2 likes 5mo

chromatogramTL410 Mar 2026#54

Collapsed as off-topic by two members at trust level 3 or above

Helpful, and short, which on this subject is harder than long.

m.adeyemiTL210 Mar 2026#55

Small correction to my own earlier position on nausea profile of amylin analogues. I had the units the wrong way round, which changes the conclusion by an order of magnitude and therefore changes it entirely.

14 likes 5mo

retention_indexTL2Analytical chemist10 Mar 2026 · edited#56

endpoint_line, post #3: Marking my uncertainty on nausea profile of amylin analogues explicitly. I am confident about the direction, much less confident about the size, and not confident at all that it generalises past the case in the first post. Go to post

Answering the question post #52 raises rather than the one it answers.

Nausea profile of amylin analogues: the historical agent pramlintide required multiple daily doses and had a difficult tolerability profile. A weekly formulation is a substantially different proposition and data from that is more relevant than data from pramlintide.

The disagreement above is smaller than it looks once the terms are fixed.

29 likes in reply to #3 5mo

r.petrovTL211 Mar 2026#57

I would rather say I do not know than round it up to an answer.

0 likes 5mo

preregisteredTL3Research methods11 Mar 2026#58

5 likes 5mo

GDashwoodTL3Regular12 Mar 2026#59

Nothing to add on the substance. Thank you for taking the question at face value.

0 likes 5mo

l.ferreiraTL212 Mar 2026#60

Post #56 describes the usual case. This is about the unusual one.

Comparing an amylin analogue to an incretin agonist on weight change alone misses that they were developed to be used together rather than instead of each other.

I would rather be precise about what I do not know than vague about what I do.

0 likes in reply to #10 5mo